Immuneering Corporation (IMRX)
NASDAQ (NMS) NASDAQ (NMS) Primary Summary
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors' data.
Immuneering (IMRX) Upgraded to Buy: Here's What You Should Know
Immuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
Immuneering Corporation Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MA mason adams PVG ASSET MANAGEMENT Corp. | 146,451 | $771,796.77 | $604,842.63 | -$166,954.14 | -21.63% |
| BG Bart Gancher Intech Investment Management LLC | 10,764 | $54,358.2 | $48,545.64 | -$5,812.56 | -10.69% |
 Joseph Castro Nuveen LLC | 438,362 | $2.19M | $2.1M | -$83,289.39 | -3.81% |
 Regan O'Neill Burkehill Global Management LP | 300,000 | $2.1M | $1.52M | -$582,000 | -27.71% |
 Li Peng China Universal Asset Management Co. Ltd. | 12,797 | $82,548.71 | $52,851.61 | -$29,697.1 | -35.98% |
Immuneering Corporation (IMRX) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Immuneering Corporation ever had a stock split?
Immuneering Corporation Profile
| Biotechnology Industry | Healthcare Sector | Benjamin J. Zeskind CEO | NASDAQ (NMS) Exchange | 45254E107 CUSIP |
| US Country | 57 Employees | - Last Dividend | - Last Split | 30 Jul 2021 IPO Date |
Overview
Immuneering Corporation is a clinical-stage oncology company dedicated to the development of innovative medicines targeting a broad spectrum of cancer patients. Established in 2008 and headquartered in Cambridge, Massachusetts, the company focuses on creating solutions to address the unmet needs of patients suffering from various types of cancer. With a commitment to advancing cancer treatment, Immuneering Corporation leverages its expertise to develop therapies that aim to improve outcomes for patients facing this challenging disease.
Products and Services
IMM-1-104: This leading product candidate from Immuneering Corporation represents a significant advancement in cancer therapy. As a dual-MEK inhibitor, IMM-1-104 is currently undergoing a Phase 1/2a clinical trial. The drug is designed to treat patients with several types of cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer. Specifically targeting mutations of RAS and/or RAF, IMM-1-104 aims to offer a new hope for patients whose cancers are driven by these genetic alterations.
IMM-6-415: Another promising addition to the company’s portfolio, IMM-6-415, is in the stage of an Investigational New Drug (IND) application. Focused on treating solid tumors, IMM-6-415 embodies the innovative approach of Immuneering Corporation to cancer treatment. By developing drugs like IMM-6-415, the company strives to expand the arsenal of therapeutic options available to patients dealing with complex, challenging tumors.
